局限期食管小细胞癌20例治疗临床分析  

Clinical analysis of 20 cases of limited stage primary esophageal small cell carcinoma

作　　者：吴敬勋[1] 叶煌阳[1] 张映红[1] 吕晓君[1] 

机构地区：[1]厦门大学附属第一医院肿瘤内科,361003

出　　处：《中国实用医药》2012年第33期10-12,共3页China Practical Medicine

摘　　要：目的分析局限期原发性食管小细胞癌(PESC)的临床特点及其诊治与预后。方法回顾性分析2004年6月至2012年2月厦门大学附属第一医院收治的20例局限期原发性食管小细胞癌临床资料,并对其治疗手段、生存预后进行分析。结果全组20例患者中位无进展生存(PFS)5.7个月(3.9～7.5个月,95%CI),中位生存(OS)16.1个月(9.3～23.0个月,95%CI)。15例曾接受化学治疗(术前新辅助化疗、放疗中同步化疗或术后辅助化疗)患者的PFS显著高于未接受化学治疗的患者(9.9月vs 3.7月,P=0.02),但化疗与否并不影响总生存。结论食管小细胞癌目前尚无标准治疗模式。但包含了化学治疗的综合治疗可能是一种值得进一步探讨和推荐的治疗方式。Objective To evaluate the clinical characteristics,treatment and prognosis in patients with primary esophageal small cell carcinoma（PESC）.Methods Clinical characteristics,therapy modalities and prognosis of 20 PESC patients treated in the first affiliated hospital of Xiamen university from June.2004 to Feb.2012 were retrospectively reviewed.Results The median progression free survival（PFS） and overall survival（OS） of the 20 patients were 5.7 months（3.9~7.5 months,95%CI） and 16.1 months（9.3~23.0 months,95%CI） respectively.The PFS of 15 patients who had received chemotherapy（including neo-adjuvant chemotherapy,concurrent radiochemotherapy and adjuvant chemotherapy） was longer than that of patients who had not received chemotherapy（9.9 months vs 3.7 months,P=0.02）.But chemotherapy had no influence in OS.Conclusion The standard treatment modality for PESC is still uncertain.Chemo-based multi-modality therapy may be an optimal and recommended choice that needed further discussion.

关 键 词：食管肿瘤 小细胞癌 治疗 预后 

分 类 号：R735.1[医药卫生—肿瘤]